MedTrace Logo

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

NCT05785754 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2025-06-26

No results posted yet for this study

Summary

This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors. The study consists of an Escalation Phase (Phase 1a) and a Dose Expansion/Optimization Phase (Phase 1b).

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

DRUG

DCSZ11

A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.

DRUG

Pembrolizumab

Pembrolizumab injection

DRUG

Doxorubicin

1b SOC Cohort 1: Doxorubicin combination in soft tissue sarcoma

DRUG

Tebentafusp

1b SOC Cohort 2: Tebentafusp combination in uveal melanoma

Sponsors & Collaborators

  • DynamiCure Biotechnology

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-28
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05785754 on ClinicalTrials.gov